Roche Announces Thomas Schinecker as New President of 454 Life Sciences

18-Jul-2011 - USA

454 Life Sciences, a center of excellence of Roche’s business unit Applied Science,  announced that effective August 1, 2011, Dr. Thomas Schinecker is appointed Lifecycle Leader for Sequencing and President of 454 Life Sciences, Inc., in Branford, Connecticut, USA, reporting to Robert Yates, Head of Applied Science.

Dr. Schinecker is currently the Diagnostics General Manager of Sweden, located in Bromma, a suburb of Stockholm.  Dr. Schinecker’s extensive background and experience of over eight years at Roche will be instrumental in guiding 454 Life Sciences into the next generation of pyrosequencing. Dr. Schinecker holds a PhD in oncology, studying at the New York University. He then excelled in several leadership positions in the Sales & Marketing organization of Roche Diagnostics Austria, starting his career at Roche in the Perspectives Program in 2003. With his success in several key management positions within Roche Diagnostics, Dr. Schinecker brings the required organizational and operating skills to 454 Life Sciences’ highly innovative and accurate long sequence read technology. 454 Sequencing Systems are used productively by large numbers of life science researchers in cancer, infectious disease, immunogenetics, drug discovery, agriculture and other disciplines, resulting in more than 1,000 peer-reviewed publications.

Other news from the department people

Most read news

More news from our other portals

Last viewed contents

BGU researchers develop new fast test to tell bacterial and viral infections apart - Prof. Robert Marks and multi-disciplinary team tracked the immune system’s response to infection

Cellomics and GE Healthcare Collaborate To Provide Faster and More Effective Cellular Screening - Software Development and Commercialization Agreement Offers Informatics Solution for High Content Screening

NeuroVive and to-BBB awarded Eurostars grant for development of stroke therapy

Oxford Nanopore Announces Licence Agreement with Harvard University for Graphene DNA sequencing

to-BBB starts manufacturing collaboration with TTY Biopharm for brain cancer treatment

HealthLinx and InSymbiosis to co-develop therapeutic for lung disease

TxCell achieves positive results for Col-Treg in a model of autoimmune uveitis

Genomatix Wins BioChance Grant for $1.6 Mio Research Project into RNAi Mediated Regulatory Networks

Clearbridge BioMedics makes a big impact at the 2012 Asian Innovation Awards

Kansas State University professor's USDA research shows mad cow disease also caused by genetic mutation

BASF applies for European approval for Fortuna, a disease-resistant table potato

A replay of life: What happens in our brain when we die? - Scientists recorded the activity of a dying human brain, revealing rhythmic wave patterns similar to those that occur during dreaming and meditation

A replay of life: What happens in our brain when we die? - Scientists recorded the activity of a dying human brain, revealing rhythmic wave patterns similar to those that occur during dreaming and meditation